Chemkart India H1 FY27 Revenue Doubles to ₹20,587 Lakhs

H1 FY27 (April 2026 - September 2026) Results:

Revenue from Operations: ₹20,587.3 lakhs, representing 99.4% YoY growth from H1 FY26 (₹10,322.6 lakhs) and 84.5% growth from H2 FY26 (₹11,160.4 lakhs)
EBITDA: ₹2,937.0 lakhs, up 107.5% YoY with margin improvement of 60 bps to 14.3%
Profit After Tax: ₹2,255.9 lakhs, up 122.2% YoY with PAT margin improvement of 120 bps to 11.0%
EPS: ₹18.65 (based on profit after tax)

Standalone Performance (H1 FY27):

EZRM SEZ Facility Construction:

Full-scale construction underway at JNPT Special Economic Zone, Maharashtra
4,120 sq.m plot leased for 60 years at JNPA SEZ, Raigad
Facility designed for nutraceutical CDMO operations with focus on advanced technologies including microencapsulation, liposomal delivery systems, and enhanced bioavailability formats
Construction progress includes RCC structural development, PEB warehouse structure erection, and compound wall construction
55 personnel deployed at construction site
Bhumi Pujan ceremony held on July 19, 2025

Business Overview:

B2B supplier of raw ingredients for nutritional, sports, and health supplements
Key products include amino acids (L-Leucine, L-Isoleucine, L-Valine, L-Lysine HCL), creatine monohydrate, whey protein concentrate, and specialty ingredients
28,259 sq. ft. warehousing facility in Bhiwandi, Maharashtra with blending, grinding, packing, labeling, and sealing operations
ISO 9001:2015, ISO 22000:2018, HALAL, and KOSHER certifications
Subsidiaries: Easy Raw Materials Private Limited (manufacturing & export) and Vinstar Biotech Private Limited (biotech & life sciences)

India's nutraceutical market growing at 10.3% CAGR, projected to reach USD 85 billion by 2033
Key growth segments: sports & performance nutrition, protein fortification, metabolic & cognitive wellness, healthy ageing, and advanced formulation technologies
Government incentives including PLI schemes and FSSAI regulations supporting domestic manufacturing

Chairman & Managing Director Ankit Shailesh Mehta highlighted:

H1 FY27 performance nearly matched company's entire FY26 revenue in six months
Margin improvement reflects strength of business model and growing customer trust
Continued investment in EZRM SEZ manufacturing facility as key milestone
Focus on research and development, product innovation, and advanced nutraceutical technologies
Healthy business visibility and strong sales pipeline for H2 FY27

Assets:

Total Assets: ₹21,851.7 lakhs (vs. ₹15,707.5 lakhs in Mar 2026)
Non-Current Assets: ₹3,307.3 lakhs including Property, Plant & Equipment (₹817.9 lakhs), Capital Work in Progress (₹956.9 lakhs), and Other Non-current Assets (₹1,518.0 lakhs)
Current Assets: ₹18,544.4 lakhs including Inventories (₹4,376.8 lakhs), Trade Receivables (₹8,949.8 lakhs), Cash & Cash Equivalents (₹3,302.0 lakhs)

Liabilities & Equity:

Total Equity: ₹15,228.0 lakhs including Share Capital (₹1,209.9 lakhs) and Reserves & Surplus (₹14,018.1 lakhs)
Current Liabilities: ₹6,433.0 lakhs including Short Term Borrowings (₹2,029.6 lakhs) and Trade Payables (₹3,430.1 lakhs)

Chairman & Managing Director: Ankit Shailesh Mehta (Chemical Engineering graduate, MBA in Technology Management, 11+ years entrepreneurial experience)
Promoter & Executive Director: Parul Shailesh Mehta (9 years nutraceutical sector experience, science graduate)
Promoter & Executive Director: Shailesh Vinodrai Mehta (Commerce graduate, 30+ years chemical sector experience)

Investor Relations Partner: X-B4 Advisory LLP (Rasika Sawant / Aagam Shah)